Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18570873
Hong F, et al. (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30, 701-11 18570873
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, melanoma skin cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), WM35 (melanocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin no change compared to control

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, melanoma skin cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), WM35 (melanocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin no change compared to control
siRNA RICTOR (human) decrease
siRNA TSC2 (human) increase

T157-p - p27Kip1 (human)
Modsite: GIRkrPAtDDSSTQN SwissProt Entrez-Gene
Orthologous residues
p27Kip1 (human): T157‑p, p27Kip1 (mouse): A157‑p, p27Kip1 (rat): A157‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, melanoma skin cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), WM35 (melanocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE SGK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE SGK1 (human) pharmacological activator of upstream enzyme, transfection of inactive enzyme, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody, transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease
insulin, estradiol increase
rapamycin estradiol, insulin inhibit treatment-induced increase
amino_acids increase
rapamycin amino_acids inhibit treatment-induced increase
siRNA amino_acids SGK1 (human) inhibit treatment-induced increase
siRNA RICTOR (human) decrease
siRNA Raptor (human) decrease
siRNA TSC2 (human) increase
Downstream Regulation
Effect of modification (function):  intracellular localization

T198-p - p27Kip1 (human)
Modsite: PGLRRRQt_______ SwissProt Entrez-Gene
Orthologous residues
p27Kip1 (human): T198‑p, p27Kip1 (mouse): T197‑p, p27Kip1 (rat): T197‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, melanoma skin cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), WM35 (melanocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE SGK1 (human)
Downstream Regulation
Effect of modification (function):  intracellular localization

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, melanoma skin cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), WM35 (melanocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease
insulin, estradiol increase
rapamycin estradiol, insulin inhibit treatment-induced increase
amino_acids increase
rapamycin amino_acids inhibit treatment-induced increase
siRNA Raptor (human) decrease

T256-p - SGK1 (human)
Modsite: EHNSTTStFCGTPEY SwissProt Entrez-Gene
Orthologous residues
SGK1 (human): T256‑p, SGK1 iso2 (human): T351‑p, SGK1 iso3 (human): T270‑p, SGK1 (mouse): T256‑p, SGK1 (rat): T256‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, melanoma skin cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), WM35 (melanocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease
insulin, estradiol increase
rapamycin estradiol, insulin inhibit treatment-induced increase
amino_acids increase
rapamycin amino_acids inhibit treatment-induced increase
siRNA Raptor (human) decrease
siRNA TSC2 (human) increase

S422-p - SGK1 (human)
Modsite: AEAFLGFsYAPPTDS SwissProt Entrez-Gene
Orthologous residues
SGK1 (human): S422‑p, SGK1 iso2 (human): S517‑p, SGK1 iso3 (human): S436‑p, SGK1 (mouse): S422‑p, SGK1 (rat): S421‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, melanoma skin cancer
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), WM35 (melanocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE mTOR (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE mTOR (human) pharmacological activator of upstream enzyme, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease
insulin, estradiol increase
rapamycin estradiol, insulin inhibit treatment-induced increase
amino_acids increase
rapamycin amino_acids inhibit treatment-induced increase
siRNA Raptor (human) decrease
siRNA TSC2 (human) increase